Indomethacin & SARS-CoV-2: Prospects for clinical management of the inflammatory state

Severe acute respiratory syndrome - (SARS) is a pandemic (called as SARS-CoV-2 or COVID-19), severely affected by transmission and fatal disease caused unknown coronavirus family of RNA virus (SARS-COV). Humans are under great threat among other species were non-identified. Phenotype can range from asymptomatic to fulminate cytokine storm which leads multiorgan failure resulting death. Still the world eagerly waiting for antiviral drug stop corona infection. Previous studies found that indomethacin had ability inhibit DNA replication. Objectives . Interleukins (IL), Interferons (IFN) metabolites like cyclopentane cyclooxygenase (COX 1/COX 2) active against several viruses. Experts have divided SARS infection in three phases (Phase-1, 2, 3) based on severity In phase-3 there was due exuberant inflammation observed damage organs even fatal. We investigated effect COX inhibitor replication reducing hyper inflammatory state. this article we tried assess clinical management SARS-COV-2 Indomethacin. Results Indomethacin cause relief pain taking deep breath infected patients. be considered safe effective prevention treatment also activity. Conclusion : potent CoV-2.